This seems to be the news we've been waiting for with confirmation of the company's lenses superiority with paediatric myopia but the market's response has been underwhelming. Presumably a small number of holders sold out yesterday when there was no uptick in the price on release of the announcement as there seems to be nothing negative in the announcement. The result was excellent. Perhaps the study size of 32 patients wasn't enough to satisfy some? I saw Canaccord's report briefly. Their target of 65c is less than exciting. One number stood out though, p<0.00000. I expect they picked it up from the research rather than the company's report of it. I am hoping that the price will kick over the next few days as overseas investors become aware of the news.
VTI Price at posting:
39.0¢ Sentiment: Buy Disclosure: Held
